Can Fite Biopharma Stock Net Income
| CANF Stock | 1.00 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Can Fite's long-term financial health and intrinsic value.
Can |
Can Fite Biopharma Company Net Income Analysis
Can Fite's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Can Fite Net Income | (12.62 M) |
Most of Can Fite's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Can Fite Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Can Fite Biopharma reported net income of (12.62 Million). This is 103.7% lower than that of the Biotechnology sector and 118.01% lower than that of the Health Care industry. The net income for all Israel stocks is 102.21% higher than that of the company.
Can Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Can Fite's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Can Fite could also be used in its relative valuation, which is a method of valuing Can Fite by comparing valuation metrics of similar companies.Can Fite is currently under evaluation in net income category among its peers.
Can Fundamentals
| Return On Equity | -1.34 | |||
| Return On Asset | -0.5 | |||
| Operating Margin | (13.51) % | |||
| Current Valuation | 35.67 M | |||
| Shares Outstanding | 1.01 B | |||
| Price To Earning | (337.46) X | |||
| Price To Book | 2.84 X | |||
| Price To Sales | 85.87 X | |||
| Revenue | 853 K | |||
| Gross Profit | 853 K | |||
| EBITDA | (12.83 M) | |||
| Net Income | (12.62 M) | |||
| Cash And Equivalents | 3.21 M | |||
| Cash Per Share | 0.07 X | |||
| Current Ratio | 2.75 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (9.86 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 6.0 | |||
| Beta | 0.79 | |||
| Market Capitalization | 41.28 M | |||
| Total Asset | 20.25 M | |||
| Net Asset | 20.25 M |
About Can Fite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Can Stock
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.